CTI BioPharma Stock Price, News & Analysis (NASDAQ:CTIC)

$3.73 +0.03 (+0.81 %)
(As of 02/19/2018 05:00 AM ET)
Previous Close$3.70
Today's Range$3.70 - $3.79
52-Week Range$2.45 - $4.79
Volume487,800 shs
Average Volume447,345 shs
Market Capitalization$234.90 million
P/E Ratio-3.13
Dividend YieldN/A
Beta0.5

About CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTIC
CUSIPN/A
Phone206-282-7100

Debt

Debt-to-Equity Ratio0.26%
Current Ratio2.19%
Quick Ratio2.17%

Price-To-Earnings

Trailing P/E Ratio-3.13445378151261
Forward P/E Ratio-3.11
P/E GrowthN/A

Sales & Book Value

Annual Sales$57.40 million
Price / Sales4.09
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book13.81

Profitability

Trailing EPS($1.19)
Net Income$-52,000,000.00
Net Margins-96.91%
Return on Equity-209.67%
Return on Assets-50.35%

Miscellaneous

Employees100
Outstanding Shares62,980,000

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

Shares of CTI BioPharma reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The biopharmaceutical company had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. View CTI BioPharma's Earnings History.

When will CTI BioPharma make its next earnings announcement?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for CTI BioPharma.

Where is CTI BioPharma's stock going? Where will CTI BioPharma's stock price be in 2018?

1 equities research analysts have issued 12 month price targets for CTI BioPharma's stock. Their predictions range from $7.50 to $7.50. On average, they expect CTI BioPharma's stock price to reach $7.50 in the next twelve months. View Analyst Ratings for CTI BioPharma.

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:

  • Laurent Fischer M.D., Chairman of the Board (Age 52)
  • Adam R. Craig M.D., Ph.D., President, Chief Executive Officer, Director (Age 51)
  • David H. Kirske, Chief Financial Officer, Executive Vice President (Age 62)
  • Bruce J. Seeley, Chief Operating Officer (Age 53)
  • Jack W. Singer M.D., Interim Chief Medical Officer, Global Head of Translational Medicine, Executive Vice President, Chief Scientific Officer (Age 72)
  • Nancy L. Boman Ph.D., Senior Vice President of Clinical Development and Regulatory Affairs
  • Monique M. Greer, Senior Vice President of Corporate Communications and Investor Relations (Age 48)
  • Michael A. Metzger, Director (Age 45)
  • Matthew Perry, Director
  • David Ross Parkinson M.D., Independent Director (Age 67)

Who owns CTI BioPharma stock?

CTI BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include STONEPINE CAPITAL MANAGEMENT, LLC (5.00%), STONEPINE CAPITAL MANAGEMENT, LLC (5.00%), Stonepine Capital Management LLC (4.27%), Renaissance Technologies LLC (1.42%), Kennedy Capital Management Inc. (0.57%) and Jane Street Group LLC (0.41%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, Jack W Singer, James A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Who sold CTI BioPharma stock? Who is selling CTI BioPharma stock?

CTI BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG and Geode Capital Management LLC. View Insider Buying and Selling for CTI BioPharma.

Who bought CTI BioPharma stock? Who is buying CTI BioPharma stock?

CTI BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Kennedy Capital Management Inc., Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy CTI BioPharma stock?

Shares of CTI BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTI BioPharma stock can currently be purchased for approximately $3.73.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $234.90 million and generates $57.40 million in revenue each year. The biopharmaceutical company earns $-52,000,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. CTI BioPharma employs 100 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 600, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (CTIC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CTI BioPharma (NASDAQ:CTIC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 3.003.003.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$7.50$7.50
Price Target Upside: 131.48% upside131.48% upside131.48% upside114.29% upside

CTI BioPharma (NASDAQ:CTIC) Consensus Price Target History

Price Target History for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Jefferies GroupInitiated CoverageBuy -> Buy$7.50HighView Rating Details
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

CTI BioPharma (NASDAQ:CTIC) Earnings History and Estimates Chart

Earnings by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.30)N/AView Earnings Details
11/6/2017Q3 2017($0.32)($0.28)$0.30 million$1.71 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)$0.03$22.23 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.70)($0.71)$0.75 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.70)($0.23)$9.14 millionViewListenView Earnings Details
11/8/2016Q3 2016($0.70)($1.00)$4.43 millionViewN/AView Earnings Details
8/4/2016Q2($0.10)($0.07)$7.36 millionViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01$36.48 millionViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)$11.32 millionViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03$21.52 million$39.53 millionViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)$11.79 million$1.34 millionViewListenView Earnings Details
4/29/2014Q114($0.20)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
10/30/2013Q3 2013($1.70)($2.00)$2.00 million$0.36 millionViewN/AView Earnings Details
7/31/2013Q2 2013($1.70)($1.70)$1.50 million$0.31 millionViewN/AView Earnings Details
5/2/2013Q1 2013($4.40)($1.80)$1.13 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
8/1/2012Q2 2012($7.15)ViewN/AView Earnings Details
4/20/2012Q1 2012($5.00)($4.30)ViewN/AView Earnings Details
3/7/2012Q4 2011($4.00)($7.40)ViewN/AView Earnings Details
10/25/2011Q3 2011($5.50)($8.00)ViewN/AView Earnings Details
7/28/2011Q2 2011($6.00)($6.80)ViewN/AView Earnings Details
4/27/2011Q1 2011($6.00)($17.40)ViewN/AView Earnings Details
2/16/2011Q4 2010($6.00)($12.00)ViewN/AView Earnings Details
10/28/2010Q3 2010($18.00)($6.60)ViewN/AView Earnings Details
8/5/2010Q2 2010($6.00)($23.10)ViewN/AView Earnings Details
4/28/2010Q1 2010($22.20)ViewN/AView Earnings Details
2/11/2010Q4 2009($9.00)($14.40)ViewN/AView Earnings Details
11/5/2009Q3 2009($27.89)ViewN/AView Earnings Details
8/6/2009Q2 2009($15.00)($15.30)ViewN/AView Earnings Details
5/7/2009Q1 2009($80.98)($26.99)ViewN/AView Earnings Details
3/16/2009Q4 2008($287.94)($162.57)ViewN/AView Earnings Details
11/7/2008Q3 2008($1,019.80)($850.03)ViewN/AView Earnings Details
8/18/2008Q2 2008($1,049.79)($1,406.72)ViewN/AView Earnings Details
5/8/2008Q1 2008($1,409.72)($2,303.54)ViewN/AView Earnings Details
3/13/2008Q4 2007($1,649.67)($2,231.55)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CTI BioPharma (NASDAQ:CTIC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.68)($0.68)($0.68)
Q4 20181($0.60)($0.60)($0.60)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for CTI BioPharma (NASDAQ:CTIC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CTI BioPharma (NASDAQ CTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.16%
Institutional Ownership Percentage: 42.84%
Insider Trades by Quarter for CTI BioPharma (NASDAQ:CTIC)
Institutional Ownership by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Bvf Partners L P/IlMajor ShareholderBuy5,634,108$3.00$16,902,324.00View SEC Filing  
2/9/2018Value Fund L P BiotechnologyInsiderBuy6,333,333$3.00$18,999,999.00View SEC Filing  
9/29/2017Richard L LoveDirectorSell14,600$3.21$46,866.0084,318View SEC Filing  
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.001,780,133View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.001,790,133View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.001,800,133View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.001,810,133View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.951,820,133View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00598,784View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.001,054,892View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.002,138,302View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.002,148,302View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00600,084View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.001,054,992View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.002,248,302View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00610,084View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.002,258,302View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.002,258,302View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.001,306,850View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00620,084View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.001,321,850View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.002,951,519View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00906,347View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.002,961,519View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00921,347View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.001,336,850View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00931,347View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00640,084View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.001,351,850View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.003,221,519View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00530,449View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00941,347View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.001,451,850View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33725,084View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00649,214View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.001,260,919View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00812,897View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00468,937View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00448,619View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.001,035,234View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.002,402,794View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00620,904View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25401,170View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CTI BioPharma (NASDAQ CTIC) News Headlines

Source:
DateHeadline
CTI BioPharma (CTIC) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowCTI BioPharma (CTIC) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:37 PM
Jefferies Group Analysts Increase Earnings Estimates for CTI BioPharma Corp (CTIC)Jefferies Group Analysts Increase Earnings Estimates for CTI BioPharma Corp (CTIC)
www.americanbankingnews.com - February 15 at 11:40 AM
CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare ConferenceCTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 14 at 4:49 PM
CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common StockCTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
finance.yahoo.com - February 13 at 9:10 AM
CTI BioPharma Corp (CTIC) Major Shareholder Bvf Partners L. P/Il Acquires 5,634,108 SharesCTI BioPharma Corp (CTIC) Major Shareholder Bvf Partners L. P/Il Acquires 5,634,108 Shares
www.americanbankingnews.com - February 13 at 12:28 AM
Insider Buying: CTI BioPharma Corp (CTIC) Insider Purchases 6,333,333 Shares of StockInsider Buying: CTI BioPharma Corp (CTIC) Insider Purchases 6,333,333 Shares of Stock
www.americanbankingnews.com - February 13 at 12:28 AM
Bio-Path (BPTH) versus CTI BioPharma (CTIC) Financial ComparisonBio-Path (BPTH) versus CTI BioPharma (CTIC) Financial Comparison
www.americanbankingnews.com - February 10 at 5:02 PM
CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common StockCTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
www.prnewswire.com - February 9 at 7:31 AM
CTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock - StreetInsider.comCTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock - StreetInsider.com
www.streetinsider.com - February 6 at 9:09 AM
BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor ConferenceBrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
www.prnewswire.com - February 6 at 5:55 AM
CTI BioPharma (CTIC) Launches Follow-On Offering of Common StockCTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock
www.streetinsider.com - February 5 at 4:22 PM
CTI BioPharma Announces Launch of Follow-On OfferingCTI BioPharma Announces Launch of Follow-On Offering
finance.yahoo.com - February 5 at 9:09 AM
Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?
finance.yahoo.com - January 30 at 9:35 AM
CTI BioPharma Provides Corporate and European Regulatory UpdateCTI BioPharma Provides Corporate and European Regulatory Update
finance.yahoo.com - January 26 at 9:16 AM
How Is Novartis’s Kymriah Positioned for 2018?How Is Novartis’s Kymriah Positioned for 2018?
finance.yahoo.com - January 23 at 4:03 PM
BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22
www.prnewswire.com - January 16 at 6:24 AM
What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?
finance.yahoo.com - January 10 at 5:13 PM
Zacks Investment Research Lowers CTI BioPharma (CTIC) to HoldZacks Investment Research Lowers CTI BioPharma (CTIC) to Hold
www.americanbankingnews.com - January 2 at 11:26 PM
ETFs with exposure to CTI BioPharma Corp. : January 1, 2018ETFs with exposure to CTI BioPharma Corp. : January 1, 2018
finance.yahoo.com - January 1 at 5:08 PM
Financial Survey: CTI BioPharma (CTIC) vs. Qiagen (QGEN)Financial Survey: CTI BioPharma (CTIC) vs. Qiagen (QGEN)
www.americanbankingnews.com - December 30 at 11:13 AM
Head-To-Head Analysis: CTI BioPharma (CTIC) versus Ironwood Pharmaceuticals (IRWD)Head-To-Head Analysis: CTI BioPharma (CTIC) versus Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - December 29 at 1:58 AM
CTI BioPharma (CTIC) Raised to "Buy" at Zacks Investment ResearchCTI BioPharma (CTIC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - December 27 at 8:19 PM
CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 9:42 AM
ETFs with exposure to CTI BioPharma Corp. : December 21, 2017ETFs with exposure to CTI BioPharma Corp. : December 21, 2017
finance.yahoo.com - December 21 at 5:15 PM
CTI BioPharma Loses Strength As The Company Faces Sharp ... - Seeking AlphaCTI BioPharma Loses Strength As The Company Faces Sharp ... - Seeking Alpha
seekingalpha.com - December 21 at 9:37 AM
Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?
finance.yahoo.com - December 15 at 5:50 PM
35 Stocks Moving In Wednesdays Pre-Market Session - Benzinga35 Stocks Moving In Wednesday's Pre-Market Session - Benzinga
www.benzinga.com - November 29 at 9:40 AM
Is CTI BioPharma Corp (CTIC) Undervalued?Is CTI BioPharma Corp (CTIC) Undervalued?
finance.yahoo.com - November 20 at 6:39 PM
ETFs with exposure to CTI BioPharma Corp. : November 10, 2017ETFs with exposure to CTI BioPharma Corp. : November 10, 2017
finance.yahoo.com - November 10 at 5:33 PM
CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference - PR Newswire (press release)CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 10 at 7:01 AM
FY2017 Earnings Forecast for CTI BioPharma Corp. Issued By Jefferies Group (CTIC)FY2017 Earnings Forecast for CTI BioPharma Corp. Issued By Jefferies Group (CTIC)
www.americanbankingnews.com - November 9 at 8:16 AM
CTI BioPharmas (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaCTI BioPharma's (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 11:26 PM
CTI BioPharma to Present at the Jefferies 2017 London Healthcare ConferenceCTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:22 AM
Edited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 6:03 AM
EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q3 Earnings ReportEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q3 Earnings Report
www.rttnews.com - November 7 at 12:00 AM
CTI BioPharma Corp. (CTIC) Announces  Earnings Results, Beats Estimates By $0.04 EPSCTI BioPharma Corp. (CTIC) Announces Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - November 6 at 11:07 PM
CTI BioPharma Reports Third Quarter 2017 Financial Results - PR Newswire (press release)CTI BioPharma Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 6 at 6:57 PM
CTI BioPharma Corp. to Host Earnings CallCTI BioPharma Corp. to Host Earnings Call
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma Reports Third Quarter 2017 Financial ResultsCTI BioPharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma reports 3Q lossCTI BioPharma reports 3Q loss
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017
finance.yahoo.com - October 30 at 6:13 PM
CTI BioPharma Corp. (CTIC) to Release Earnings on MondayCTI BioPharma Corp. (CTIC) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
ETFs with exposure to CTI BioPharma Corp. : October 26, 2017ETFs with exposure to CTI BioPharma Corp. : October 26, 2017
finance.yahoo.com - October 26 at 2:34 PM
Analyzing CTI BioPharma Corp. (CTIC) & Its PeersAnalyzing CTI BioPharma Corp. (CTIC) & Its Peers
www.americanbankingnews.com - October 19 at 6:26 AM
ETFs with exposure to CTI BioPharma Corp. : October 16, 2017ETFs with exposure to CTI BioPharma Corp. : October 16, 2017
finance.yahoo.com - October 16 at 6:21 PM
ValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong SellValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong Sell
www.americanbankingnews.com - October 11 at 10:26 PM
CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 6:44 AM
ETFs with exposure to CTI BioPharma Corp. : October 2, 2017ETFs with exposure to CTI BioPharma Corp. : October 2, 2017
finance.yahoo.com - October 3 at 6:44 AM
CTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in StockCTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in Stock
www.americanbankingnews.com - October 2 at 8:02 PM
CTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in AugustCTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in August
www.americanbankingnews.com - September 17 at 1:20 AM

SEC Filings

CTI BioPharma (NASDAQ:CTIC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CTI BioPharma (NASDAQ:CTIC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CTI BioPharma (NASDAQ CTIC) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.